◎ Sugi Atlas

Atlas / Drug / Dronabinol

Dronabinol

drug
On this page

Also known as ABBOTT 40566ABBOTT-40566Dronabinol component of ad-313Dronabinol component of ad313Dronabinol component of sci-110J882FMarinolNSC-134454QCD 84924QCD-84924SP 104SP-104SyndrosTetrahydrocannabinolSID144206169TetrahydrocannabinoTetrahydrocannabidiol

Summary

Dronabinol (CHEMBL465) is an approved small-molecule non-narcotic analgesic (ATC A04AD10) targeting GPR55, GLRA1, and GLRA2; indicated across 38 conditions including neoplasm and osteoarthritis, knee.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: A04AD10
  • Targets: 10 (GPR55, GLRA1, GLRA2…)
  • Indications: 38 conditions
  • Clinical trials: 123
  • Chemistry: 314.5 Da · C21H30O2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL465
NameDronabinol
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID16078
ChEBICHEBI:66964
ATCA04AD10
Molecular formulaC21H30O2
Molecular weight314.5
InChIKeyCYQFCXCEBYINGO-IAGOWNOFSA-N

SMILES: CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O

IUPAC name: (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol

ChEBI definition: A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.

Pharmacological roles (ChEBI): non-narcotic analgesic, hallucinogen, cannabinoid receptor agonist, epitope.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: ABBOTT 40566, ABBOTT-40566, Dronabinol, Dronabinol component of ad-313, Dronabinol component of ad313, Dronabinol component of sci-110, J882F, Marinol, NSC-134454, QCD 84924, QCD-84924, SP 104

Patent coverage: 18,893 distinct patent families (62,107 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 62,096 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
GPR55GPR55Agonist8.10%Q9Y2T6
GLRA1glycine receptor α1 subunitPotentiation5.50.3%P23415
GLRA2glycine receptor α2 subunitPotentiation60.4%P23416
GLRA3glycine receptor α3 subunitPotentiation5.30.2%O75311
TRPA1TRPA1Agonist4.90.1%O75762
TRPM8TRPM80.5%Q7Z2W7
TRPV2TRPV2Activation4.851.4%Q9Y5S1
CNR1CB1 receptorPartial agonist7.40%P21554
CNR2CB2 receptorPartial agonist7.5P34972
GPR18GPR18Full agonist6.020.2%Q14330

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: Transient receptor potential cation channel subfamily M member 8, G-protein coupled receptor 55, Cannabinoid receptor, Cannabinoid receptor, Cannabinoid receptor 1, Monoacylglycerol lipase ABHD6, Fatty-acid amide hydrolase 1, D(3) dopamine receptor, N-arachidonyl glycine receptor, Cannabinoid receptor 2.

Bioactivity

ChEMBL activities: 98 potent at pChembl ≥ 5 of 107 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
CNR28.85EC501.42nMCHEMBL_ACT_25843663
CNR28.82EC501.5nMCHEMBL_ACT_2461951
CNR18.55IC502.8nMCHEMBL_ACT_7979616
CNR18.54Ki2.9nMCHEMBL_ACT_2461949
CNR28.48Ki3.3nMCHEMBL_ACT_1969447
CNR18.41Ki3.88nMCHEMBL_ACT_13321921
CNR18.41Ki3.88nMCHEMBL_ACT_14534795
P202728.24IC505.8nMCHEMBL_ACT_152416
P202728.24IC505.8nMCHEMBL_ACT_518599
CNR18.17EC506.73nMCHEMBL_ACT_25843659
P479368.14EC507.3nMCHEMBL_ACT_19115084
P479368.04Ki9.2nMCHEMBL_ACT_1969427
CNR28.02IC509.5nMCHEMBL_ACT_7979620
CNR18Ki10nMCHEMBL_ACT_8042686
DRD37.99EC5010.2nMCHEMBL_ACT_18036514
P202727.96EC5011nMCHEMBL_ACT_706208
CNR27.92EC5012nMCHEMBL_ACT_23296357
CNR27.91EC5012.3nMCHEMBL_ACT_14999703
P477467.82Ki15.3nMCHEMBL_ACT_15448413
CNR17.77Ki17nMCHEMBL_ACT_1969448
CNR17.77EC5017nMCHEMBL_ACT_8042716
CNR17.75Ki18nMCHEMBL_ACT_15626768
CNR17.75Ki18nMCHEMBL_ACT_25917766
CNR17.66Ki22nMCHEMBL_ACT_14999673
CNR17.66Ki22nMCHEMBL_ACT_23296350
CNR27.62Ki24nMCHEMBL_ACT_8042779
CNR27.6Ki25nMCHEMBL_ACT_1215574
CNR17.54Ki28.5nMCHEMBL_ACT_1215573
CNR27.52Ki30nMCHEMBL_ACT_29092155
CNR27.49Ki32.2nMCHEMBL_ACT_706207

Target pathways

Aggregated over 10 target gene(s): GPR55, GLRA1, GLRA2, GLRA3, TRPA1, TRPM8, TRPV2, CNR1, CNR2, GPR18.

Top Reactome pathways

4 total, by targets touching each:

PathwayTargetsGenes
Class A/1 (Rhodopsin-like receptors)4CNR1, CNR2, GPR18, GPR55
G alpha (i) signalling events4CNR1, CNR2, GPR18, GPR55
Neurotransmitter receptors and postsynaptic signal transmission3GLRA1, GLRA2, GLRA3
TRP channels3TRPA1, TRPM8, TRPV2

Dominant GO biological processes

GO termTargets
monoatomic ion transport6
monoatomic ion transmembrane transport6
G protein-coupled receptor signaling pathway4
signal transduction4
cannabinoid signaling pathway3
chloride transport3
chloride transmembrane transport3
excitatory postsynaptic potential3
calcium ion transmembrane transport3
calcium ion transport3
transmembrane transport3
adenylate cyclase-activating G protein-coupled receptor signaling pathway3
neuropeptide signaling pathway2
cellular response to amino acid stimulus2
cellular response to zinc ion2

Indications & clinical

Indications

38 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070MONDO:0004992
osteoarthritis, knee3MONDO:0005416EFO:0004616
anorexia nervosa3MONDO:0005351MONDO:0005351
irritable bowel syndrome2MONDO:0005052EFO:0000555
obstructive sleep apnea syndrome2MONDO:0007147EFO:0003918
HIV infectious disease2MONDO:0005109EFO:0000764
post-traumatic stress disorder2MONDO:0005146EFO:0001358
Tourette syndrome2MONDO:0007661EFO:0004895
opiate dependence2MONDO:0005530EFO:0005611
dementia2MONDO:0001627HP:0000726
cannabis dependence2MONDO:0005689EFO:0007191
psoriatic arthritis2MONDO:0011849EFO:0003778
neuralgia2MONDO:0021667EFO:0005762
amyotrophic lateral sclerosis2MONDO:0004976MONDO:0004976
multiple sclerosis2MONDO:0005301MONDO:0005301
migraine with aura2MONDO:0005475MONDO:0005475
sickle cell disease2MONDO:0011382MONDO:0011382
migraine without aura2MONDO:0100431MONDO:0100431
autism spectrum disorder2MONDO:0005258EFO:0003756
rheumatoid arthritis2MONDO:0008383EFO:0000685
trichotillomania2MONDO:0013189MONDO:0013189
drug dependence1MONDO:0005303EFO:0003890
essential tremor1MONDO:0003233EFO:0003108
type 2 diabetes mellitus1MONDO:0005148MONDO:0005148
alcohol abuse1MONDO:0002046MONDO:0007079
bipolar disorder1MONDO:0004985MONDO:0004985
arthropathy0MONDO:0006816HP:0003040
mental disorder0MONDO:0005084EFO:0000677

10 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 123.

Phase distribution

PhaseTrials
PHASE133
PHASE229
Not specified17
EARLY_PHASE113
PHASE2/PHASE311
PHASE47
PHASE37
PHASE1/PHASE26

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00965809PHASE4UNKNOWNAdd on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD)
NCT01598207PHASE4COMPLETEDThe Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain
NCT02472847PHASE4COMPLETEDCannabinoid Control of Fear Extinction Neural Circuits in Humans
NCT02569073PHASE4WITHDRAWNInvestigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain
NCT04155008PHASE4TERMINATEDNutrition and Pharmacological Algorithm for Oncology Patients Study
NCT04374773PHASE4COMPLETEDEffects of Pregnancy-associated Hormones on THC Metabolism in Women
NCT05820685PHASE4TERMINATEDDronabinol On the Pain Experience
NCT05335252PHASE3ACTIVE_NOT_RECRUITINGDronabinol After Arthroscopic Surgery
NCT06146101PHASE2/PHASE3ACTIVE_NOT_RECRUITINGRePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA
NCT07148206PHASE3NOT_YET_RECRUITINGDronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
NCT07231965PHASE2/PHASE3NOT_YET_RECRUITINGSynthetic THC And Blood Pressure
NCT07422311PHASE2/PHASE3NOT_YET_RECRUITINGTo Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer’s Disease
NCT07570953PHASE2/PHASE3NOT_YET_RECRUITINGA Study Of Synthetic THC And Sleep
NCT00153192PHASE2/PHASE3COMPLETEDStudy to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain
NCT00553059PHASE3COMPLETEDPalonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
NCT00642512PHASE3COMPLETEDDronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
NCT00760695PHASE3COMPLETEDCannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa
NCT00959218PHASE3COMPLETEDEfficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis
NCT01020019PHASE2/PHASE3COMPLETEDCombined Pharmacotherapy for Cannabis Dependency
NCT01024335PHASE2/PHASE3COMPLETEDDronabinol Naltrexone Treatment for Opioid Dependence
NCT01598896PHASE2/PHASE3TERMINATEDCombination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
NCT02283281PHASE2/PHASE3UNKNOWNAnesthetic Premedication With a Cannabis Extract (Cannapremed)
NCT03530800PHASE2/PHASE3COMPLETEDDronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors
NCT04298528PHASE3UNKNOWNA RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty
NCT05283161PHASE2/PHASE3UNKNOWNCBD (Cannabidiol)/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann)
NCT05269628PHASE2RECRUITINGMechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
NCT05519111PHASE2RECRUITINGCannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
NCT06381180PHASE1/PHASE2NOT_YET_RECRUITINGWarrior CARE: Cannabis Behavioral Health
NCT06446479PHASE2RECRUITINGEffects of THC on Alcohol Consumption and Neural Correlates of Reward
NCT06454669PHASE2RECRUITINGDronabinol as an Adjunct for Reducing Pain
NCT06477952PHASE1/PHASE2RECRUITINGDRonabinol Treatment of OSA
NCT06731894PHASE2RECRUITINGPhytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
NCT07225777PHASE2RECRUITINGSex Differences in Neurobehavioral Response to THC
NCT00079560PHASE1/PHASE2COMPLETEDComparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS
NCT00217971PHASE2COMPLETEDDronabinol Treatment for Marijuana Addiction
NCT00316563PHASE2COMPLETEDOrexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study
NCT00373503PHASE2COMPLETEDEffect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse
NCT00377468PHASE2UNKNOWNEffect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study)
NCT00418925PHASE2UNKNOWNEfficacy of Dronabinol for the Treatment of Cervical Dystonia
NCT00480441PHASE2COMPLETEDEffectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

175 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CANNABIDIOLChEMBL + PubChemPhase 4 (approved)CNR1, CNR2, GLRA2, GPR18, GPR55, TRPM8, TRPV2
CANNABIDIVARINChEMBLPhase 2CNR1, CNR2, GPR55, TRPA1, TRPM8, TRPV2
TETRAHYDROCANNABIVARINChEMBLPhase 2CNR1, CNR2, GPR55, TRPA1, TRPM8, TRPV2
CANNABIGEROLChEMBLPhase 2CNR1, CNR2, TRPA1, TRPM8, TRPV2
RIMONABANTChEMBLPhase 4 (approved)CNR1, CNR2, GPR18, GPR55
CANNABINOLChEMBLPhase 3CNR1, CNR2, TRPA1, TRPV2
CaffeineChEMBL + PubChemPhase 4 (approved)CNR1, TRPA1
ECONAZOLEChEMBL + PubChemPhase 4 (approved)CNR1, TRPM8
MEFLOQUINEChEMBL + PubChemPhase 4 (approved)CNR1, GLRA1
FLUSPIRILENEChEMBLPhase 4 (approved)CNR1, GLRA1
MENTHOLChEMBLPhase 4 (approved)TRPA1, TRPM8
NABILONEChEMBLPhase 4 (approved)CNR1, CNR2
DEXANABINOLChEMBLPhase 3CNR1, CNR2
EPIGALOCATECHIN GALLATEChEMBLPhase 3CNR1, CNR2
ICILLINChEMBLPhase 3TRPA1, TRPM8
LENABASUMChEMBLPhase 3CNR1, CNR2
LEVOMENTHOLChEMBLPhase 3TRPA1, TRPM8
OTENABANTChEMBLPhase 3CNR1, CNR2
TARANABANTChEMBLPhase 3CNR1, CNR2
DELTA-8-TETRAHYDROCANNABINOLChEMBLPhase 2CNR1, CNR2
IBIPINABANTChEMBLPhase 2CNR1, CNR2
PRS-211375ChEMBLPhase 2CNR1, CNR2
REDAFAMDASTATChEMBLPhase 2CNR1, CNR2
S-777469ChEMBLPhase 2CNR1, CNR2
SURINABANTChEMBLPhase 2CNR1, CNR2
TEDALINABChEMBLPhase 2CNR1, CNR2
EugenolPubChemApprovedTRPA1, TRPM8
menthol, unspecified formPubChemApprovedTRPA1, TRPM8
SerotoninPubChemApprovedGLRA1, TRPM8
ADAPALENEChEMBL + PubChemPhase 4 (approved)GLRA1
CAPSAICINChEMBL + PubChemPhase 4 (approved)TRPM8
CHOLECALCIFEROLChEMBL + PubChemPhase 4 (approved)GLRA1
CINACALCETChEMBL + PubChemPhase 4 (approved)GLRA1
CLOTRIMAZOLEChEMBL + PubChemPhase 4 (approved)TRPM8
DICLOFENACChEMBL + PubChemPhase 4 (approved)TRPA1
DISULFIRAMChEMBL + PubChemPhase 4 (approved)TRPA1
DUTASTERIDEChEMBL + PubChemPhase 4 (approved)GLRA1
GLYCINEChEMBL + PubChemPhase 4 (approved)GLRA1
MEFENAMIC ACIDChEMBL + PubChemPhase 4 (approved)TRPA1
PIMOZIDEChEMBL + PubChemPhase 4 (approved)GLRA1
REGORAFENIBChEMBL + PubChemPhase 4 (approved)GLRA1
RISPERIDONEChEMBL + PubChemPhase 4 (approved)GLRA1
SULINDACChEMBL + PubChemPhase 4 (approved)GLRA1
TAFAMIDISChEMBL + PubChemPhase 4 (approved)CNR1
TELMISARTANChEMBL + PubChemPhase 4 (approved)GLRA1
ACARBOSEChEMBLPhase 4 (approved)CNR1
ALCLOMETASONE DIPROPIONATEChEMBLPhase 4 (approved)CNR1
ALPRAZOLAMChEMBLPhase 4 (approved)CNR1
AMCINONIDEChEMBLPhase 4 (approved)CNR1
AMPRENAVIRChEMBLPhase 4 (approved)CNR1
ASTEMIZOLEChEMBLPhase 4 (approved)GLRA1
ATENOLOLChEMBLPhase 4 (approved)CNR1
BECLOMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)CNR1
BEPRIDILChEMBLPhase 4 (approved)CNR1
BIFONAZOLEChEMBLPhase 4 (approved)CNR1
BISACODYLChEMBLPhase 4 (approved)GPR55
BUCLIZINEChEMBLPhase 4 (approved)CNR1
BUSPIRONEChEMBLPhase 4 (approved)CNR1
CALCITRIOLChEMBLPhase 4 (approved)CNR1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)CNR1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot